Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31152634 | 1.00 | ALDH1A1 (0.73) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL14157781 | 0.93 | CYP3A4 (0.65) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL21294247 | 0.86 | SMN1; SMN2 (0.80) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL31036037 | 0.86 | SMN1; SMN2 (0.80) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL21765699 | 0.86 | RAB9A (0.72) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL9291930 | 0.84 | MEN1 (1.00) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL12731414 | 0.84 | RAB9A (0.71) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL11710607 | 0.84 | MAPT (0.74) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL11710601 | 0.84 | MEN1 (0.74) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL521958 | 0.84 | MAPT (1.00) | ALDH1A1MEN1KMT2ACYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-2343299-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2474545-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2426129-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2455382-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-7829568-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| EP-1869038-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-07-08 | — | — | EP | disclosed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ALDH1A1 1511/4885MEN1 1064/4885KMT2A 3392/4885 |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | CD4, CD40LG, CD14 | ALDH1A1 2899/4885MEN1 4376/4885KMT2A 4046/4885 |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | CYP3A7, CYP3A5, CYP2D6 | ALDH1A1 538/4885MEN1 626/4885KMT2A 2117/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | ALDH1A1 1985/4885MEN1 3895/4885KMT2A 3492/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ALDH1A1 1511/4885MEN1 1064/4885KMT2A 3392/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | ALDH1A1 245/4885MEN1 1023/4885KMT2A 2643/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | ALDH1A1 1511/4885MEN1 1064/4885KMT2A 3392/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | ALDH1A1 2753/4885MEN1 2962/4885KMT2A 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.